START- STRATEGIC TIMING OF ANTIRETROVIRAL THERAPY

开始——抗逆转录病毒治疗的战略时机

• 批准号: 8166579
• 负责人: DANIEL W NIXON
• 金额: $ 0.07万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166579
• 关键词: Acquired Immunodeficiency Syndrome; Adverse event; Aspirin; Bacterial Pneumonia; Blood Pressure; Caring; Cessation of life; Computer Retrieval of Information on Scientific Projects Database; Congestive Heart Failure; Coronary; Coronary Arteriosclerosis; Deep Vein Thrombosis; Development; Diabetes Mellitus; Dialysis procedure; Electrocardiogram; End stage renal failure; Funding; Grant; HIV; HIV drug resistance; Hospitalization; Institution; Kidney Transplantation; Lipids; Liver diseases; Malignant Neoplasms; Myocardial Infarction; Outcome; Peripheral arterial disease; Pharmaceutical Preparations; Proteinuria; Protocols documentation; Pulmonary Embolism; Quality of life; Research; Research Personnel; Resources; Risk Behaviors; Skin Cancer; Source; Squamous Cell; Stroke; Time; United States National Institutes of Health; antiretroviral therapy; blood lipid; cost; health care service utilization; mortality; secondary outcome; transmission process

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this protocol is to determine whether early ART is superior to deferred ART in delaying the occurrence of a composite outcome consisting of HIV-AIDS, non-AIDS, or death from any cause. Secondary Objectives include: a. To compare early ART to deferred ART for each component of the primary composite endpoint: ¿ AIDS or death from AIDS ¿ Non-AIDS or death not attributable to AIDS b. To compare early ART to deferred ART for the following secondary outcomes: ¿ All-cause mortality ¿ Non-AIDS ¿ CVD (myocardial infarction, stroke, coronary revascularizaton) ¿ ESRD (initiation of dialysis, renal transplantation) ¿ Decompensated liver disease ¿ Non-AIDS malignancy, excluding basal and squamous cell skin cancers ¿ Non-AIDS malignancy, including basal and squamous cell skin cancers ¿ AIDS ¿ Bacterial pneumonia ¿ Adverse events ¿ Hospitalization ¿ Quality of life ¿ Health-care utilization and cost of care ¿ HIV transmission risk behavior ¿ HIV drug resistance ¿ Pulmonary embolism or deep vein thrombosis ¿ New-onset diabetes mellitus ¿ Coronary artery disease requiring drug treatment ¿ Congestive heart failure ¿ Peripheral arterial disease ¿ Change in estimated GFR and development of proteinuria ¿ Blood pressure and blood lipids ¿ ECG abnormalities ¿ Use of blood pressure- or lipid-lowering treatment or aspirin

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该方案的主要目的是确定早期ART在延迟复合结局发生方面是否优于延迟ART的上级效果 包括艾滋病、非艾滋病或任何原因的死亡。 次要目的包括： a.比较早期ART与延迟ART的主要复合终点的每个组成部分： 艾滋病或死于艾滋病 非艾滋病或非艾滋病所致死亡 B.比较早期ART与延迟ART的以下次要结局： 全因死亡率 非艾滋病 心血管疾病（心肌梗死、中风、冠状动脉血运重建） ESRD（开始透析、肾移植） 失代偿性肝病 非艾滋病恶性肿瘤，不包括基底细胞和鳞状细胞皮肤癌 非艾滋病恶性肿瘤，包括基底细胞和鳞状细胞皮肤癌 艾滋病 细菌性肺炎 不良事件 住院治疗 生活质量 卫生保健利用率和保健费用 艾滋病毒传播危险行为 艾滋病毒耐药性 肺栓塞或深静脉血栓 新发糖尿病 需要药物治疗的冠心病 充血性心力衰竭 外周动脉疾病 估计GFR的变化和蛋白尿的发生 血压和血脂 ECG异常 使用降压或降脂治疗或阿司匹林